GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway InhibitionAidan G. Gilmartin, Sylvie Laquerre|Clinical Cancer Research|2011Cited by 600
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin LesionsAlastair J. King, Sylvie Laquerre|PLoS ONE|2013Cited by 216
Characterization of <i>In Vivo</i> Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of ResistanceKristina B. Emdal, Forest M. White, Sheri L. Moores et al.|Molecular Cancer Therapeutics|2017Cited by 31
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Sylvie Laquerre|iScience|2025Cited by 5
Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistanceKristina B. Emdal, Forest M. White, Antje Dittmann et al.|PMC|2017Cited by 3